var data={"title":"Calcium gluconate: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Calcium gluconate: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5793?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=calcium-gluconate-drug-information\" class=\"drug drug_general\">see &quot;Calcium gluconate: Drug information&quot;</a> and <a href=\"topic.htm?path=calcium-gluconate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Calcium gluconate: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6026083\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Cal-Glu [OTC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1003045\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antidote, Hydrofluoric Acid</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Calcium Salt</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Electrolyte Supplement, Oral</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Electrolyte Supplement, Parenteral</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11442188\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Adequate intake (AI): </b>Oral: 200 mg/day of <b>elemental calcium</b>; requirements may vary on prematurity, postnatal age, and other clinical factors; serum calcium concentrations should be monitored closely to determine patient-specific needs (IOM 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Enteral nutrition, maintenance requirement (dietary intake; formula, breastmilk):</b> Preterm neonates, birth weight &lt;2,000 g: Oral: 150 to 220 mg/kg/day of <b>elemental calcium</b> (Abrams 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cardiac arrest in the presence of hyperkalemia or hypocalcemia, hypermagnesemia, or calcium channel blocker toxicity:</b> Dose expressed as calcium gluconate: IV, I.O.: 60 to 100 mg/kg/<b>dose</b>; may repeat in 10 minutes if necessary; if effective, consider IV infusion (Avery 1994; Hegenbarth 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypocalcemia</b>: Dose depends on clinical condition and serum calcium concentration; monitor closely: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>General dosing: </i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dose expressed as <b>calcium gluconate</b>: IV:  200 mg/kg every 6 to 12 hours or 400 mg/kg/day as a continuous infusion (Avery 1994;  Scott 1984)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dose expressed as <b>elemental calcium</b>: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV: Usual range: 40 to 75 mg/kg/day as a continuous infusion (Cloherty 2012; MacDonald 2016); for asymptomatic hypocalcemia tapering regimen has been suggested: Initial: 80 mg/kg/day as a continuous infusion for 48 hours then reduce to 40 mg/kg/day continuous infusion typically for 24 hours (once normal serum calcium concentration documented) (Jain 2010) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral: 50 to 150 mg/kg/day in 4 to 6 divided doses; not to exceed 1,000 mg/<b>day</b> (MacDonald 2016; Rigo 2007). <b>Note:</b> In general, other calcium salts may be more preferable oral dosage forms in neonatal patients; however, the 10% calcium gluconate injection may be given orally (Mimouni 1994).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Symptomatic (ie, seizures, tetany):</i> Dose expressed as <b>calcium gluconate</b>: IV: 100 to 200 mg/kg/<b>dose</b> over 5 to 10 minutes; followed by a continuous infusion 500 to 800 mg/kg/day (Cloherty 2012; Jain 2010; Mimouni 1994; Nelson 1996; Root 1976; Zhou 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Parenteral nutrition, maintenance requirement:</b> Dose expressed as <b>elemental calcium</b>: IV: 2 to 4 <b>mEq</b>/kg/day (Mirtallo 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Rickets (radiographic evidence), treatment:</b> Dose expressed as <b>elemental calcium</b>: Oral: Initial: 20 mg/kg/day in 2 to 4 divided doses, increased as tolerated to usual range of 60 to 70 mg/kg/day in 2 to 4 divided doses; maximum daily dose of 80 mg/kg/day (Abrams 2013; Avery 1994)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1003071\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=calcium-gluconate-drug-information\" class=\"drug drug_general\">see &quot;Calcium gluconate: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Adequate intake (AI)</b> (IOM 2011): Dose expressed as <b>elemental calcium:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">1 to 6 months: 200 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">7 to 12 months: 260 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Recommended daily allowance (RDA)</b> (IOM 2011): Dose expressed as <b>elemental calcium;</b> during pregnancy and lactation, requirements may change: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">1 to 3 years: 700 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">4 to 8 years: 1,000 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">9 to 18 years: 1,300 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Parenteral nutrition, maintenance requirement</b> (Mirtallo 2004): <b>Note:</b> Dose expressed as <b>elemental calcium:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children &le;50 kg:  0.5 to 4 <b>mEq</b>/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &gt;50 kg and Adolescents: 10 to 20 <b>mEq</b>/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hypocalcemia:</b> Dose depends on clinical condition and serum calcium concentration:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>General dosing:</i> Infants, Children, and Adolescents: Dose expressed as <b>calcium gluconate</b>: IV: 200 to 500 mg/kg/day as a continuous infusion or in 4 divided doses; maximum dose: Infants and Children: 1,000 mg/dose; Adolescents: 2,000 to 3,000 mg/dose (Edmondson 1990; Zhou 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Symptomatic (ie, seizures, tetany):</i> Infants, Children, and Adolescents: Dose expressed as <b>calcium gluconate</b>: IV: 100 to 200 mg/kg/dose over 5 to 10 minutes; usual adult dose: 1,000 to 2,000 mg/dose; may repeat after 6 hours or follow with a continuous infusion of 200 to 800 mg/kg/day (Edmondson 1990; Kelly 2013; Misra 2008; Nelson 1996; Zhou 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Chronic therapy in asymptomatic patient:</i> Infants and Children: Dose expressed as <b>calcium gluconate</b>: Oral: 500 mg/kg/day in divided doses every 4 to 8 hours (Nelson 1996); <b>Note:</b> In general, other oral calcium salts (eg, carbonate, glubionate) are a more preferable oral dosage form option in young pediatric patients; however, the 10% calcium gluconate injection may be given orally (Mimouni 1994).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Rickets (due to vitamin D deficiency); treatment:</b> Infants and Children:  Dose expressed as <b>elemental calcium</b>: Oral: 30 to 75 mg/kg/day in 3 divided doses; begin at higher end of range and titrate downward over 2 to 4 weeks (Misra 2008). <b>Note:</b> In general, other oral calcium salts (eg, carbonate, glubionate) are a more preferable oral dosage formulation option in young pediatric patients; however, the 10% calcium gluconate injection may be given orally (Mimouni 1994).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cardiac arrest in the presence of hyperkalemia or hypocalcemia, hypermagnesemia, or calcium channel blocker toxicity:</b> Infants, Children, and Adolescents: Dose expressed as <b>calcium gluconate</b>: IV, I.O.: 60 to 100 mg/kg/<b>dose</b> (maximum dose: 3,000 mg); may repeat in 10 minutes if necessary; if effective, consider IV infusion (Hegenbarth 2008). <b>Note:</b> Routine use in cardiac arrest is not recommended due to the lack of improved survival (PALS [Kleinman] 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Calcium channel blocker toxicity; hypotension/conduction disturbances:</b> Infants, Children, and Adolescents: Dose expressed in mg of <b>calcium gluconate</b>: IV, I.O.: 60 mg/kg/<b>dose</b> administered over 30 to 60 minutes (Hegenbarth 2008). <b>Note:</b> Calcium chloride may provide a more rapid increase of ionized calcium in critically ill children. Calcium gluconate may be substituted if calcium chloride is not available.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hydrofluoric acid burns, treatment:</b> Limited data available: Children and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">SubQ: 5% to 10% solution: 0.5 <b>mL</b>/cm<sup>2</sup> of burned tissue (Dibbell 1970; Hatzifotis 2004; Kirkpatrick 1995; Krenzelok 1999). Infiltration should be carried 0.5 cm away from the margin of the injured tissue into the surrounding uninjured areas. Repeat if pain recurs. Local anesthesia may be required to perform procedure; pain resolution is the therapeutic endpoint and if a local anesthetic is utilized, it may be difficult to determine the success of therapy. <b>Note:</b> <b>Never</b> use calcium chloride for subcutaneous injection.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intra-arterial: Add 10 <b>mL</b> of a 10% solution to 50 mL of D<sub>5</sub>W. Infuse over 4 hours into the artery that provides the vascular supply to the affected area (Hatzifotis 2004; Kirkpatrick 1995). Pain usually resolves by the end of the infusion; repeat if pain recurs. <b>This intervention should be used only by those accustomed to this technique. Extreme care should be taken to avoid the extravasation.</b> A poison information center or clinical toxicologist should be consulted prior to implementation.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Inhalation: 2.5% nebulization solution: Mix 1.5 <b>mL</b> of 10% calcium gluconate solution with 4.5 mL NS to make a 2.5% solution and administer via nebulization (Upfal 1990).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Note:</b> Dose expressed in terms of the <b>calcium gluconate salt</b> (unless otherwise specified as elemental calcium). Doses expressed in terms of the <b>calcium gluconate salt</b> are based on a solution concentration of 100 mg/mL (10%) containing 0.465 mEq (9.3 mg)/mL elemental calcium, except where noted.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Recommended daily allowance (RDA)</b> (IOM 2011): <b>Note:</b> Expressed in terms of <b>elemental calcium</b>: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Females/Males:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">19 to 50 years: 1,000 mg <b>elemental calcium</b> daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&ge;51 years, females: 1,200 mg <b>elemental calcium</b> daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">51 to 70 years, males: 1,000 mg <b>elemental calcium</b> daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Females, pregnant/lactating: Requirements are the same as in nonpregnant or nonlactating females</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Hypocalcemia:</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Intermittent IV:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Mild [ionized calcium: 4 to 5 mg/dL (1 to 1.2 mmol/L)]: 1,000 to 2,000 mg over 2 hours; asymptomatic patients may be given oral calcium (Ariyan 2004; French 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Moderate to severe [without seizure or tetany; ionized calcium: &lt;4 mg/dL (&lt;1 mmol/L)]: 4000 mg over 4 hours (French 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Severe symptomatic (eg, seizure, tetany): 1,000 to 2,000 mg over 10 minutes; repeat every 60 minutes until symptoms resolve (French 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <b>Note:</b> Repeat ionized calcium measurement 6 to 10 hours after completion of administration. Check for hypomagnesemia  and correct if present. Consider continuous infusion if hypocalcemia is likely to recur due to ongoing losses (French 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Continuous IV infusion: 5 to 20 mg/kg/hour (Pai 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Cardiac arrest or cardiotoxicity in the presence of hyperkalemia, hypocalcemia, or hypermagnesemia:</b> IV: 1,500 to 3,000 mg over 2 to 5 minutes (Vanden Hoek 2010); <b>Note:</b> Routine use in cardiac arrest is not recommended due to the lack of improved survival (Neumar 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Maintenance electrolyte requirements for parenteral nutrition:</b> IV (Mirtallo 2004): <b>Note:</b> Expressed in terms of <b>elemental calcium</b>: 10 to 20 mEq daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Infants, Children, Adolescents, and Adults: No initial dosage adjustment necessary; however, accumulation may occur with renal impairment and subsequent doses may require adjustment based on serum calcium concentrations.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Infants, Children, Adolescents, and Adults: No initial dosage adjustment necessary; subsequent doses should be guided by serum calcium concentrations. In adult patients in the anhepatic stage of liver transplantation, equal rapid increases in ionized concentrations occur suggesting that calcium gluconate does not require hepatic metabolism for release of ionized calcium (Martin 1990).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144645\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cal-Glu: 500 mg [dye free]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10% (10 mL, 50 mL, 100 mL); 1% in Dextrose 5% (100 mL); 1% in NaCl 0.9% (100 mL); 2% in Dextrose 5% (50 mL, 100 mL); 2% in NaCl 0.9% (50 mL, 100 mL); 3% in NaCl 0.9% (100 mL); 4% in NaCl 0.9% (50 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10% (10 mL, 50 mL, 100 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Prefilled Syringe, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 4% in NaCl 0.9% (50 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg, 500 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144630\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21879420\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=calcium-gluconate-drug-information\" class=\"drug drug_general\">see &quot;Calcium gluconate: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">1 g calcium gluconate = elemental calcium 93 mg = calcium 4.65 mEq = calcium 2.33 mmol</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1003076\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Administer with plenty of fluids with or following meals. The 10% calcium gluconate injection may be administered orally in young pediatric patients (Mimouni 1994)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Do not inject calcium salts IM or administer SubQ since severe necrosis and sloughing may occur; extravasation of calcium can result in severe necrosis and tissue sloughing. Do not use scalp vein or small hand or foot veins for IV administration. Not for endotracheal administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV:  Administer undiluted slowly (~1.5 mL calcium gluconate 10% per minute; not to exceed 200 mg/minute except in emergency situations; consider cardiac monitoring) through a small needle into a large vein in order to avoid too rapid increases in the serum calcium and extravasation. In acute situations of symptomatic hypocalcemia, infusions over 5 to 10 minutes have been described in pediatric patients (Kelly 2013; Misra  2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV infusion: Administer at a rate not to exceed 200 mg/minute. <b>Note:</b> Due to the potential presence of particulates, American Regent, Inc recommends the use of a 0.22 micron in-line filter for IV administration of admixture (1.2 micron filter if admixture contains lipids) (Important Drug Administration Information, American Regent 2013); a similar recommendation has not been noted by other manufacturers. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Parenteral nutrition solution: Calcium-phosphate stability  in parenteral nutrition solutions is dependent upon the pH of the solution, temperature, and relative concentration of each ion. The pH of the solution is primarily dependent upon the amino acid concentration. The higher the percentage amino acids the lower the pH, the more soluble the calcium and phosphate. Individual commercially available amino acid solutions vary significantly with respect to pH lowering potential and consequent calcium phosphate compatibility; consult product specific labeling for additional information. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Vesicant; ensure proper needle or catheter placement prior to and during IV infusion. Avoid extravasation. If extravasation occurs, stop infusion immediately and disconnect (leave needle/cannula in place); gently aspirate extravasated solution (do NOT flush the line); initiate hyaluronidase antidote (See Management of Drug Extravasations for more details); remove needle/cannula; apply dry cold compresses (Hurst 2004); elevate extremity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2847084\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Store intact vials at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Do not freeze. Discard unused portion within 4 hours after initial puncture.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Store at room temperature; consult product labeling for specific requirements.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1003046\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Treatment of hypocalcemia and conditions secondary to hypocalcemia (eg, tetany, seizures, arrhythmias); treatment of cardiac disturbances secondary to hyperkalemia; adjunctive treatment of rickets, osteomalacia, and magnesium sulfate overdose; decrease capillary permeability in allergic conditions, nonthrombocytopenic purpura, and exudative dermatoses (eg, dermatitis herpetiformis, pruritus secondary to certain drugs) (All indications: FDA approved in all ages); has also been used for calcium channel blocker toxicity, hydrofluoric acid burns, and as a supplement in total parenteral nutrition admixtures</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Dietary supplementation of calcium (OTC: FDA approved in adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144690\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Calcium gluconate may be confused with calcium glubionate, cupric sulfate</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Calcium gluconate may be confused with calcium chloride.</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Confusion with the different intravenous salt forms of calcium has occurred. There is a threefold difference in the primary cation concentration between calcium gluconate (in which 1 g = 4.65 mEq [90 mg] of elemental Ca++) and calcium chloride (in which 1 g = 14 mEq [270 mg] of elemental Ca++).</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Prescribers should specify which salt form is desired. Dosages should be expressed either as mEq, mg, or grams of the salt form.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144687\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Arrhythmia, bradycardia, cardiac arrest, decreased blood pressure, syncope, vasodilation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Anxiety, feeling hot</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Unusual taste (chalky)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Tingling sensation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144652\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypercalcemia; concomitant use of IV calcium gluconate with ceftriaxone in neonates (&le;28 days of age).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144634\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extravasation: Parenteral calcium is a vesicant; ensure proper catheter or needle position prior to and during infusion. Avoid extravasation; adverse events from extravasation can be devastating (eg, profound tissue necrosis). Monitor the IV site closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; GI effects: Constipation, bloating, and gas are common with oral calcium supplements (especially carbonate salt).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperphosphatemia: Use with caution in patients with severe hyperphosphatemia as elevated levels of phosphorus and calcium may result in soft tissue and pulmonary arterial calcium-phosphate precipitation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypokalemia: Use with caution in patients with severe hypokalemia as acute rises in serum calcium levels may result in life-threatening cardiac arrhythmias.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypomagnesemia: Hypomagnesemia is a common cause of hypocalcemia; therefore, correction of hypocalcemia may be difficult in patients with concomitant hypomagnesemia. Evaluate serum magnesium and correct hypomagnesemia (if necessary), particularly if initial treatment of hypocalcemia is refractory.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Kidney stones (calcium-containing): Use caution when administering calcium supplements to patients with a history of kidney stones.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with chronic renal failure to avoid hypercalcemia; frequent monitoring of serum calcium and phosphorus is necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Aluminum: The parenteral product may contain aluminum; toxic aluminum concentrations may be seen with high doses, prolonged use, or renal dysfunction. Premature neonates are at higher risk due to immature renal function and aluminum intake from other parenteral sources. Parenteral aluminum exposure of &gt;4 to 5 mcg/kg/day is associated with CNS and bone toxicity; tissue loading may occur at lower doses (Federal Register 2002). See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate product selection: Multiple salt forms of calcium exist; close attention must be paid to the salt form when ordering and administering calcium; incorrect selection or substitution of one salt for another without proper dosage adjustment may result in serious over or under dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; IV administration: Avoid too-rapid IV administration (do not exceed 200 mg/minute in adults and 100 mg/minute in pediatric patients); may result in vasodilation, hypotension, bradycardia, arrhythmias, syncope, and cardiac arrest. Safety for long-term use has not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Oral administration: Administering oral calcium with food and vitamin D will optimize calcium absorption.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tartrazine: Some products may contain tartrazine, which may cause allergic reactions in susceptible individuals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298941\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144639\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12956&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alpha-Lipoic Acid: Calcium Salts may decrease the absorption of Alpha-Lipoic Acid. Alpha-Lipoic Acid may decrease the absorption of Calcium Salts. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bictegravir: Calcium Salts may decrease the serum concentration of Bictegravir.  Management: Bictegravir, emtricitabine, and tenofovir alafenamide can be administered with calcium salts under fed conditions, but coadministration with or 2 hours after a caclium salt is not recommended under fasting conditions.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bisphosphonate Derivatives: Calcium Salts may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral calcium supplements within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.<b> Exceptions: </b>Pamidronate; Zoledronic Acid.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Acetate: Calcium Salts may enhance the adverse/toxic effect of Calcium Acetate. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers: Calcium Salts may diminish the therapeutic effect of Calcium Channel Blockers. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: Calcium Salts may enhance the arrhythmogenic effect of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CefTRIAXone: Calcium Salts (Intravenous) may enhance the adverse/toxic effect of CefTRIAXone. Ceftriaxone binds to calcium forming an insoluble precipitate.  Management: Use of ceftriaxone with calcium-containing solutions within 48 hours of one another is contraindicated in neonates (28 days of age or younger).  In older patients, flush lines with compatible fluid between administration.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Calcium Salts may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DOBUTamine: Calcium Salts may diminish the therapeutic effect of DOBUTamine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dolutegravir: Calcium Salts may decrease the serum concentration of Dolutegravir.  Management: Administer dolutegravir at least 2 hours before or 6 hours after oral calcium. Administer dolutegravir/rilpivirine at least 4 hours before or 6 hours after oral calcium salts. Alternatively, dolutegravir and oral calcium can be taken together with food.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eltrombopag: Calcium Salts may decrease the serum concentration of Eltrombopag.  Management: Administer eltrombopag at least 2 hours before or 4 hours after oral administration of any calcium-containing product.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estramustine: Calcium Salts may decrease the absorption of Estramustine. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): May increase the serum concentration of Calcium Salts. Calcium Salts may decrease the serum concentration of Multivitamins/Fluoride (with ADE). More specifically, calcium salts may impair the absorption of fluoride. Management: Avoid eating or drinking dairy products or consuming vitamins or supplements with calcium salts one hour before or after of the administration of fluoride.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May increase the serum concentration of Calcium Salts.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphate Supplements: Calcium Salts may decrease the absorption of Phosphate Supplements.  Management: This applies only to oral phosphate and calcium administration. Administering oral phosphate supplements as far apart from the administration of an oral calcium salt as possible may be able to minimize the significance of the interaction.<b> Exceptions: </b>Sodium Glycerophosphate Pentahydrate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: Calcium Salts may decrease the absorption of Quinolones. Of concern only with oral administration of both agents. <b> Exceptions: </b>LevoFLOXacin (Oral Inhalation); Moxifloxacin (Systemic).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Strontium Ranelate: Calcium Salts may decrease the serum concentration of Strontium Ranelate.  Management: Separate administration of strontium ranelate and oral calcium salts by at least 2 hours in order to minimize this interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracyclines: Calcium Salts may decrease the serum concentration of Tetracyclines.  Management: If coadministration of oral calcium with oral tetracyclines can not be avoided, consider separating administration of each agent by several hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: May decrease the excretion of Calcium Salts. Continued concomitant use can also result in metabolic alkalosis.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thyroid Products: Calcium Salts may diminish the therapeutic effect of Thyroid Products.  Management: Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trientine: Calcium Salts may decrease the serum concentration of Trientine. Trientine may decrease the serum concentration of Calcium Salts. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin D Analogs: Calcium Salts may enhance the adverse/toxic effect of Vitamin D Analogs. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1891176\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Calcium crosses the placenta. The amount of calcium reaching the fetus is determined by maternal physiological changes. Calcium requirements are the same in pregnant and nonpregnant females (IOM 2011). Information related to use as an antidote in pregnancy is limited. In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant women if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey 2003). Medications used for the treatment of cardiac arrest in pregnancy are the same as in the non-pregnant woman. Doses and indications should follow current Advanced Cardiovascular Life Support guidelines. Appropriate medications should not be withheld due to concerns of fetal teratogenicity (Jeejeebhoy [AHA] 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3429093\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Serum calcium (ionized calcium preferred if available), phosphate, magnesium, heart rate, ECG</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15670427\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <col align=\"center\"></col>\n      <col align=\"left\"></col>\n      <col align=\"left\"></col>\n      <thead>\n        <tr>\n          <th align=\"center\"></th>\n          <th valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">Age</p></th>\n          <th valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">Normal Values</p>\n            <p style=\"text-indent:0em;\">Serum Concentration</p></th></tr></thead>\n      <tbody>\n        <tr>\n          <td rowspan=\"6\" align=\"center\">\n            <p style=\"text-indent:0em;\">Calcium, total</p></td>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Cord blood</p></td>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">9 to 11.5 mg/dL</p></td></tr>\n        <tr>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Newborn 3 to 24 hours</p></td>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">9 to 10.6 mg/dL</p></td></tr>\n        <tr>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Newborn 24 to 48 hours</p></td>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">7 to 12 mg/dL</p></td></tr>\n        <tr>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">4 to 7 days</p></td>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">9 to 10.9 mg/dL</p></td></tr>\n        <tr>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Child</p></td>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">8.8 to 10.8 mg/dL</p></td></tr>\n        <tr>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Adolescent to Adult</p></td>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">8.4 to 10.2 mg/dL</p></td></tr>\n        <tr>\n          <td rowspan=\"4\" align=\"center\">\n            <p style=\"text-indent:0em;\">Calcium, ionized, whole blood</p></td>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Cord blood</p></td>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">5 to 6 mg/dL</p></td></tr>\n        <tr>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Newborn 3 to 24 hours</p></td>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">4.3 to 5.1 mg/dL</p></td></tr>\n        <tr>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Newborn 24 to 48 hours</p></td>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">4 to 4.7 mg/dL</p></td></tr>\n        <tr>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">&ge;2 days</p></td>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">4.8 to 4.92 mg/dL (2.24 to 2.46 mEq/L)</p></td></tr></tbody></table>\n    </div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144633\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Moderates nerve and muscle performance via action potential threshold regulation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">In hydrogen fluoride exposures, calcium gluconate provides a source of calcium ions to complex free fluoride ions and prevent or reduce toxicity; administration also helps to correct fluoride-induced hypocalcemia.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144651\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Oral: Minimal unless chronic, high doses are given; predominantly in the duodenum and dependent on calcitriol and vitamin D; mean absorption of calcium intake varies with age (infants 60%, prepubertal children 28%, pubertal children 34%, adults 25%); during pregnancy, calcium absorption doubles; calcium is absorbed in soluble, ionized form; solubility of calcium is increased in an acidic environment (IOM 2011); decreased absorption occurs in patients with achlorhydria, renal osteodystrophy, steatorrhea, or uremia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Primarily in skeleton (99%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~40%, primarily to albumin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Primarily feces (75%; as unabsorbed calcium salts); urine (20%) (IOM 2011)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3425503\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">Due to a poor correlation between the serum ionized calcium (free) and total serum calcium, particularly in states of low albumin or acid/base imbalances, direct measurement of ionized calcium is recommended. If ionized calcium is unavailable, in low albumin states, the corrected <b>total</b> serum calcium may be estimated by this equation (assuming a normal albumin of 4 g/dL); [(4 &ndash; patient's albumin) x 0.8] + patient's measured total calcium</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">Elemental Calcium Content of Calcium Salts</caption>\n      <col align=\"left\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Calcium Salt</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Elemental Calcium</p>\n            <p style=\"text-indent:0em;\">(mg/1 g of salt form) </p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Calcium</p>\n            <p style=\"text-indent:0em;\">(mEq/g) </p></th></tr></thead>\n      <tbody valign=\"middle\">\n        <tr>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Calcium acetate </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">253</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">12.7</p></td></tr>\n        <tr>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Calcium carbonate</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">400</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">20</p></td></tr>\n        <tr>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Calcium chloride</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">273</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">13.6</p></td></tr>\n        <tr>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Calcium citrate</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">211</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">10.5</p></td></tr>\n        <tr>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Calcium glubionate</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">63.8</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">3.2</p></td></tr>\n        <tr>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Calcium gluconate</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">93</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">4.65</p></td></tr>\n        <tr>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Calcium lactate</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">130</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">6.5</p></td></tr>\n        <tr>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Calcium phosphate (tribasic)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">390</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">19.3</p></td></tr></tbody></table>\n    </div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323034\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Calcium Gluconate Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10% (100 mL): $36.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Calcium Gluconate-Dextrose Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g/50 mL 5% (50 mL): $14.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1GM/100ML 5% (100 mL): $14.92</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2GM/100ML 5% (100 mL): $23.35</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4GM/250ML 5% (250 mL): $41.29</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Calcium Gluconate-NaCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1GM/100ML 0.9% (100 mL): $14.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1GM/50ML 0.9% (50 mL): $13.78</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2GM/100ML 0.9% (100 mL): $22.88</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2GM/50ML 0.9% (50 mL): $25.54</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3GM/100ML 0.9% (100 mL): $33.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Calcium Gluconate-NaCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2GM/50ML 0.9% (50 mL): $23.69</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Calcium Gluconate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $16.45</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038547\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Biogam Ca (BE);</li>\n      <li>Calcedon (DE);</li>\n      <li>Calcii Gluconas (FI);</li>\n      <li>Calcimusc (HU);</li>\n      <li>Calcinate (PH);</li>\n      <li>Calcio Gluconato (AR, IT);</li>\n      <li>Calcium Braun (DE);</li>\n      <li>Calcium Gluconate (AU);</li>\n      <li>Calcium Gluconicum (BG, PL);</li>\n      <li>Calcium Gluconicum Granulatum (PL);</li>\n      <li>Calcium Pliva (PL);</li>\n      <li>Calcium Polfa (PL);</li>\n      <li>Folinex 50 (LK);</li>\n      <li>Glucal (ZA);</li>\n      <li>Gluconate de Calcium Lavoisier (FR);</li>\n      <li>Novacalc (NO)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Abrams SA, Committee on Nutrition. Calcium and vitamin D requirements of enterally fed preterm infants. <i>Pediatrics</i>. 2013;131(5):e1676-1683.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/23629620/pubmed\" target=\"_blank\" id=\"23629620\">23629620</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aluminum in large and small volume parenterals used in total parenteral nutrition. <i>Fed Regist</i>. 2002;67(244):77792-77793.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ariyan CE, Sosa JA. Assessment and management of patients with abnormal calcium. <i>Crit Care Med</i>. 2004; 32(4 Suppl):146-154.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/15064673/pubmed\" target=\"_blank\" id=\"15064673\">15064673</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Avery GB, Fletcher MA, MacDonald MG, eds. <i>Neontatology - Pathophysiology and Management of the Newborn</i>. 4th ed. Philadelphia, PA: Lippincott Company; 1994.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bailey B, &quot;Are There Teratogenic Risks Associated With Antidotes Used in the Acute Management of Poisoned Pregnant Women?&quot; <i>Birth Defects Res A Clin Mol Teratol</i>, 2003, 67(2):133-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/12769509/pubmed\" target=\"_blank\" id=\"12769509\">12769509</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Calcium gluconate [prescribing information]. Schaumberg, IL: APP Pharmaceuticals, LLC; February 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cloherty JP, Eichenwald EC, Hansen AR, Stark AR, eds. <i>Manual of Neonatal Care</i>. Philadelphia, PA: Lippincott Williams &amp; Wilkins; 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Department Health &amp; Human Services, Food Drug Administration, &quot;Aluminum in Large and Small Volume Parenterals Used in Total Parenteral Nutrition,&quot;  <i>Federal Register</i>, 2000, 65(17):4103-11.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dibbell DG, Iverson RE, Jones W, Laub DR, Madison MS. Hydrofluoric acid burns of the hand. <i>J Bone Joint Surg Am</i>. 1970;52(5):931-936.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/5479482 /pubmed\" target=\"_blank\" id=\"5479482 \">5479482 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Edmondson S, Almquist TD. Iatrogenic hypocalcemic tetany. <i>Ann Emerg Med</i>. 1990;19(8):938-940.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/2372181/pubmed\" target=\"_blank\" id=\"2372181\">2372181</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    French S, Subauste J, and Geraci S, &quot;Calcium Abnormalities in Hospitalized Patients,&quot; <i>South Med J</i>, 2012, 105(4):231-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/22475676/pubmed\" target=\"_blank\" id=\"22475676\">22475676</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hatzifotis M, Williams A, Muller M, Pegg S. Hydrofluoric acid burns. <i>Burns</i>. 2004;30(2):156-159.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/15019125 /pubmed\" target=\"_blank\" id=\"15019125 \">15019125 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hegenbarth MA and American Academy of Pediatrics Committee on Drugs, &quot;Preparing for Pediatric Emergencies: Drugs to Consider,&quot; <i>Pediatrics</i>,  2008, 121(2):433-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/18245435/pubmed\" target=\"_blank\" id=\"18245435\">18245435</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hurst S, McMillan M. Innovative solutions in critical care units: extravasation guidelines. <i>Dimens Crit Care Nurs</i>. 2004;23(3):125-128.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/15192356/pubmed\" target=\"_blank\" id=\"15192356\">15192356</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    IOM (Institute of Medicine), <i>Dietary Reference Intakes for Calcium and Vitamin D</i>, Washington, DC: The National Academies Press, 2011. Available at <a href=\"http://www.nap.edu/catalog.php?record_id=13050%20\" target=\"_blank\">http://www.nap.edu/catalog.php?record_id=13050</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jain A, Agarwal R, Sankar MJ, Deorari A, Paul VK. Hypocalcemia in the newborn. <i>Indian J Pediatr</i>. 2010;77(10):1123-1128.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/20737250/pubmed\" target=\"_blank\" id=\"20737250\">20737250</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kelly A, Levine MA. Hypocalcemia in the critically ill patient. <i>J Intensive Care Med</i>. 2013;28(3):166-177.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/21841146/pubmed\" target=\"_blank\" id=\"21841146\">21841146</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kirkpatrick JJ, Burd DA. An algorithmic approach to the treatment of hydrofluoric acid burns. <i>Burns</i>. 1995;21(7):495-499.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/8540974 /pubmed\" target=\"_blank\" id=\"8540974 \">8540974 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kleinman ME, Chameides L, Schexnayder SM, et al, &quot;Part 14: Pediatric Advanced Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&quot; <i>Circulation</i>, 2010, 122 (18 Suppl 3):876-908.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/20956230/pubmed\" target=\"_blank\" id=\"20956230\">20956230</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Krenzelok EP. &quot;Hydrofluoric Acid Exposures.&quot; <i>Clinical Environmental Health and Toxic Exposures</i>. 2nd ed, Sullivan JB and Krieger GR, eds. Philadelphia, PA: Lippincott Williams &amp; Wilkins; 1999, 798-806.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    MacDonald  MG, Seshia MMK, eds. <i>Neontatology - Pathophysiology and Management of the Newborn</i>. 7th ed. Philadelphia, PA: Wolters Kluwer; 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Martin TJ, Kang Y, Robertson KM, et al. Ionization and hemodynamic effects of calcium chloride and calcium gluconate in the absence of hepatic function. <i>Anesthesiology</i>. 1990; 73(1):62-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/2360741/pubmed\" target=\"_blank\" id=\"2360741\">2360741</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mimouni F, Tsang RC. Neonatal hypocalcemia: to treat or not to treat? (A review). <i>J Am Coll Nutr</i>. 1994;13(5):408-415.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/7836618/pubmed\" target=\"_blank\" id=\"7836618\">7836618</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mirtallo J, Canada T, Johnson D, et al, &quot;Safe Practices for Parenteral Nutrition,&quot; <i>JPEN J Parenter Enteral Nutr</i>, 2004, 28(6):S39-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/15568296/pubmed\" target=\"_blank\" id=\"15568296\">15568296</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Misra M, Pacaud D, Petryk A, Collett-Solberg PF, Kappy M, Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society. Vitamin D deficiency in children and its management: review of current knowledge and recommendations.<i> Pediatrics</i>. 2008;122(2):398-417.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/18676559/pubmed\" target=\"_blank\" id=\"18676559\">18676559</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nelson WE, Behrman RE, Kliegman RM, Arvin AM, eds. <i>Nelson Textbook of Pediatrics</i>. 15th ed. Philadelphia, PA: WR Saunders Company; 1996.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neumar RW, Otto CW, Link MS, et al, &quot;Part 8: Adult Advanced Cardiovascular Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&quot; <i>Circulation</i>, 2010, 122(18 Suppl 3):729-67.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/20956224/pubmed\" target=\"_blank\" id=\"20956224\">20956224</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pai AB. Chapter 59: disorders of calcium and phosphorus homeostasis. <i>Pharmacotherapy: A Pathophysiologic Approach</i>. 8th ed. Talbert RL, DiPiro JT, Matzke GR, et al, eds, New York, NY:McGraw-Hill, 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rigo J, Pieltain C, Salle B, Senterre J. Enteral calcium, phosphate and vitamin D requirements and bone mineralization in preterm infants. <i>Acta Paediatrica</i>. 2007;96:969-974.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/17577338/pubmed\" target=\"_blank\" id=\"17577338\">17577338</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Root AW, Harrison HE. Recent advances in calcium metabolism. II. Disorders of calcium homeostasis. <i>J Pediatr</i>. 1976;88(2):177-199.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/765441/pubmed\" target=\"_blank\" id=\"765441\">765441</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Scott SM, Ladenson JH, Aguanna JJ, Walgate J, Hillman LS. Effect of calcium therapy in the sick premature infant with early neonatal hypocalcemia. <i>J Pediatr</i>. 1984;104(5):747-751.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/6716222/pubmed\" target=\"_blank\" id=\"6716222\">6716222</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Upfal M, Doyle C. Medical management of hydrofluoric acid exposure. <i>J Occup Med</i>. 1990;32(8):726-731.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/2401930/pubmed\" target=\"_blank\" id=\"2401930\">2401930</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vanden Hoek TL, Morrison LJ, Shuster M, et al, &quot;Part 12: Cardiac Arrest in Special Situations: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&quot; <i>Circulation</i>, 2010, 122(18 Suppl 3):829-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/20956228/pubmed\" target=\"_blank\" id=\"20956228\">20956228</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wills MR and Lewin MR, &quot;Plasma Calcium Fractions and the Protein-Binding of Calcium in Normal Subjects and in Patients With Hypercalcaemia and Hypocalcaemia,&quot; <i>J Clin Pathol</i>, 1971, 24(9):856-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/5139991/pubmed\" target=\"_blank\" id=\"5139991\">5139991</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Worthley LI and Phillips PJ, &quot;Intravenous Calcium Salts,&quot; <i>Lancet</i>, 1980, 2(8186):149.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/6105319/pubmed\" target=\"_blank\" id=\"6105319\">6105319</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zhou P, Markowitz M. Hypocalcemia in infants and children. <i>Pediatr Rev</i>. 2009;30(5):190-192.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/19411338/pubmed\" target=\"_blank\" id=\"19411338\">19411338</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12956 Version 168.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F6026083\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1003045\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11442188\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1003071\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F144645\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F144630\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F21879420\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1003076\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F2847084\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1003046\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F144690\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F144687\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F144652\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F144634\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298941\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F144639\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F1891176\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F3429093\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F15670427\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F144633\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F144651\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F3425503\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323034\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038547\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12956|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=calcium-gluconate-drug-information\" class=\"drug drug_general\">Calcium gluconate: Drug information</a></li><li><a href=\"topic.htm?path=calcium-gluconate-patient-drug-information\" class=\"drug drug_patient\">Calcium gluconate: Patient drug information</a></li></ul></div></div>","javascript":null}